[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bayesian\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bayesian":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100053538",false,"NCT07698054","Toripalimab Combined With Beat Chemotherapy in the Treatment of Advanced Back-line Small Cell Lung Cancer","A Prospective, Open-label, Bayesian Adaptive Randomized Phase II Clinical Study of Toripalimab Combined With Beat Chemotherapy in the Treatment of Advanced Back-line Small Cell Lung Cancer","Inclusion Criteria:\n\n* 1.Age ≥18 years old, both male and female are acceptable.\n* 2\\. Histology and pathology diagnosis of extensive stage small cell lung cancer, and must meet the following standards:\n\n  1. always has not received the immune therapy,\n  2. Previously received immunotherapy, with the number of treatment lines ≥2 and the immunotherapy being effective(immunotherapy PFS \\> 3 months, withdrawal time \\> 3 months)\n  3. never used anlotinib,\n* 3\\. ECOG: 0 \\~ 2;\n* 4 . The expected lifetime 12 weeks or more;\n* 5\\. Major organs function normal\n\nExclusion Criteria:\n\n* 1.Those who are allergic to toripalimab or etoposide or have metabolic disorders;\n* 2.With known the special ripley sheet resistance, etoposide contraindication;\n* 3.Other circumstances that the researcher assessed as unsuitable for participation in this clinical study.","ALL","18 Years",{"count":18,"type":19},130,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","This study is a randomized, open-label, multi-center investigator-initiated clinical trial. Patients who meet the inclusion criteria receive the treatment plan stipulated in the protocol. A Bayesian design is used to explore the efficacy and safety of teprotumumab combined with pulse chemotherapy in the treatment of advanced second-line extensive-stage small cell lung cancer.",[25,26,27],"SCLC, Extensive Stage","Bayesian","Metronomic Chemotherapy","NOT_YET_RECRUITING","2026-07-09",{"date":31,"type":32},"2026-07-13","ACTUAL",{"date":34,"type":19},"2026-08-01",{"date":36,"type":19},"2030-12-31",{"name":38,"class":39},"Henan Cancer Hospital","OTHER_GOV",""]